SPY314.84-2.75 -0.87%
DIA261.04+0.22 0.08%
IXIC10,390.84-226.60 -2.13%

Sinovac Biotech Reports Receives Approval From China For Its Quadrivalent Flu Vaccine

Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced the China National Medical Products Administration (or

Benzinga · -

Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced the China National Medical Products Administration (or NMPA) issued a product license for its quadrivalent Influenza vaccine (or QIV).

Sinovac expects its QIV to be available to the China market for the 2020-2021 influenza season. QIV contains two A strains and two B strains, recommended by the WHO, and the vaccine protects a target group of 3 years and older against the influenza disease.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, “The approval of QIV demonstrates our ongoing commitment to develop vaccines against flu-related diseases. In addition to the newly approved QIV, our licensed influenza vaccine portfolio consists of Anflu®, China's first preservative-free trivalent influenza virus split vaccine; Panflu®, China's first pandemic influenza virus (H5N1) inactivated vaccine; and PANFLU.1®, the world's first influenza A H1N1 influenza virus split vaccine. By leveraging our expertise in influenza vaccine technology, Sinovac is able to provide a great variety of solutions against flu related disease."